COVID-19: Immunology and treatment options
S Felsenstein, JA Herbert, PS McNamara… - Clinical …, 2020 - Elsevier
The novel coronavirus SARS-CoV2 causes COVID-19, a pandemic threatening millions. As
protective immunity does not exist in humans and the virus is capable of escaping innate …
protective immunity does not exist in humans and the virus is capable of escaping innate …
COVID-19 convalescent plasma and clinical trials: understanding conflicting outcomes
D Focosi, M Franchini, L Pirofski… - Clinical microbiology …, 2022 - Am Soc Microbiol
Convalescent plasma (CP) recurs as a frontline treatment in epidemics because it is
available as soon as there are survivors. The COVID-19 pandemic represented the first …
available as soon as there are survivors. The COVID-19 pandemic represented the first …
Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)
Objective To investigate the effectiveness of using convalescent plasma to treat moderate
coronavirus disease 2019 (covid-19) in adults in India. Design Open label, parallel arm …
coronavirus disease 2019 (covid-19) in adults in India. Design Open label, parallel arm …
Convalescent plasma antibody levels and the risk of death from Covid-19
Background Convalescent plasma has been widely used to treat coronavirus disease 2019
(Covid-19) under the presumption that such plasma contains potentially therapeutic …
(Covid-19) under the presumption that such plasma contains potentially therapeutic …
Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience
Importance Passive antibody transfer is a longstanding treatment strategy for infectious
diseases that involve the respiratory system. In this context, human convalescent plasma …
diseases that involve the respiratory system. In this context, human convalescent plasma …
[HTML][HTML] The convalescent sera option for containing COVID-19
A Casadevall, L Pirofski - The Journal of clinical …, 2020 - Am Soc Clin Investig
As of early 2020, humanity is confronting a pandemic in severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2). SARS-CoV-2 causes coronavirus disease, abbreviated as …
coronavirus 2 (SARS-CoV-2). SARS-CoV-2 causes coronavirus disease, abbreviated as …
[HTML][HTML] Convalescent plasma: new evidence for an old therapeutic tool?
G Marano, S Vaglio, S Pupella, G Facco… - Blood …, 2016 - ncbi.nlm.nih.gov
Passive immunisation for the prevention and treatment of human infectious diseases can be
traced back to the 20 th century. The recent Ebola virus outbreak in West Africa has turned …
traced back to the 20 th century. The recent Ebola virus outbreak in West Africa has turned …
Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection
Background. Experience from treating patients with Spanish influenza and influenza A
(H5N1) suggested that convalescent plasma therapy might be beneficial. However, its …
(H5N1) suggested that convalescent plasma therapy might be beneficial. However, its …
Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study
Background The United States (US) Expanded Access Program (EAP) to coronavirus
disease 2019 (COVID-19) convalescent plasma was initiated in response to the rapid …
disease 2019 (COVID-19) convalescent plasma was initiated in response to the rapid …
Efficacy of IVIG (intravenous immunoglobulin) for corona virus disease 2019 (COVID-19): A meta-analysis
H Xiang, X Cheng, Y Li, W Luo, Q Zhang… - International …, 2021 - Elsevier
Background The benefit of IVIG (Intravenous Immunoglobulin) therapy for COVID-19
remains controversial. We performed a meta-analysis to investigate the efficacy of IVIG …
remains controversial. We performed a meta-analysis to investigate the efficacy of IVIG …